Volume 8, Number 3
Monday, January 21, 2008



In this issue: (click heading to view article)
Macular Thickness and Diabetic Retinopathy Severity in Eyes Without DME
Effect of Upper Eyelid Surgery on Corneal Topography
General Anesthesia and Preoperative Injection of Ropivacaine in Retinal Detachment Surgery
Progression to Severe ROP Predicted by Retinal Vessel Diameter
Briefly











Macular Thickness and Diabetic Retinopathy Severity in Eyes Without DME

In this retrospective observational case series, investigators examined the relationship of macular thickness (via optical coherence tomography, OCT) to retinopathy severity in patients with diabetes and no clinically detectable macular edema.

The study included 383 eyes of 383 patients of a private retina practice, including 100 normal eyes of patients who did not have diabetes, 100 eyes of patients with diabetes without retinopathy, 100 eyes of patients with diabetes and mild-to-moderate retinopathy, 35 eyes of patients with diabetes who had severe nonproliferative or proliferative retinopathy and 48 eyes of patients with diabetes with regressed proliferative retinopathy. Main outcome measures included central subfield mean thickness (CSMT), inner and outer zone measurements and total macular volume.

CSMTs were 208 +/- 22 (standard deviation, SD), 198 +/- 25, 204 +/- 26, 224 +/- 38 and 205 +/- 27 microns for normals, eyes of diabetics without retinopathy, eyes with mild-to-moderate nonproliferative retinopathy, eyes with severe nonproliferative to proliferative retinopathy and eyes with regressed proliferative retinopathy, respectively. For all groups, mean CSMT was greater in men than in women. Statistically significant differences by gender were observed for controls (mean difference 12 microns), diabetes patients without retinopathy (mean difference 14 microns) and diabetes patients with mild-to-moderate nonproliferative retinopathy (mean difference,18 microns). For increasing retinopathy severity, the probability of macular thickening detected by OCT but not detected by clinical examination increased. Fifteen percent of eyes with severe nonproliferative or proliferative retinopathy and no clinically detected edema had OCT-measured macular thickening.

The authors concluded that, because OCT measurements were gender-dependent, gender balance or statistical adjustment for gender imbalances of compared groups in OCT studies of diabetic macular edema is important. As retinopathy severity increases, the probability of subclinical edema rises. Except for an individual baseline measurement, possibly useful for longitudinal comparison, the data suggests that there is little reason to obtain OCT routinely in eyes with diabetes and no retinopathy or mild-to-moderate diabetic retinopathy when clinical examination fails to show macular edema.


SOURCE: Browning DJ, Fraser CM, Clark S. The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmol 2007; Dec 5 [Epub ahead of print].
Table of Contents












Effect of Upper Eyelid Surgery on Corneal Topography

This study by Swiss researchers compared the effects of different upper eyelid procedures on corneal topography.

Eighty-two eyes of 43 patients with various degrees of dermatochalasis or ptosis underwent computed corneal topography before surgery and at three months after surgery. Patients were divided into groups depending on the extent of surgery. Thickness of the central cornea was also correlated with the change in astigmatism.

Mean changes in total astigmatism of 0.25 diopters (D) after ptosis surgery and 0.21D after blepharoplasty were observed, with reduction of large fat pads, compared with 0.09D in patients after skin-only blepharoplasty. A correlation was also observed between corneal thickness and change in astigmatism of more than 0.2 cylinders after ptosis surgery. Postoperative astigmatic axis changes were not systematic.

The findings emphasize the importance of advising patients, especially those with ptosis and severe dermatochalasis, that upper eyelid repositioning procedures may induce vision changes.

SOURCE: Zinkernagel MS, Ebneter A, Ammann-Rauch D. Effect of upper eyelid surgery on corneal topography. Arch Ophthalmol 2007;125(12):1610-2.
Table of Contents






General Anesthesia and Preoperative Injection of Ropivacaine in Retinal Detachment Surgery

Swedish investigators conducted a randomized double-masked controlled clinical trial to evaluate the effects of preoperative sub-Tenon"s capsule injection of ropivacaine on intraoperative hemodynamics, postoperative pain, nausea and recovery in patients undergoing scleral buckling surgery under general anesthesia (GA).

The study included 98 patients with primary rhegmatogenous retinal detachment undergoing scleral buckling surgery under GA. Random allocation to either preoperative sub-Tenon"s capsule injection of 3 ml of 0.75% ropivacaine or sub-Tenon"s capsule injection of 3 ml of saline (control participants) immediately before a scleral buckling procedure under GA. Researchers recorded intraoperative monitoring of hemodynamic parameters, need of analgesia with sevoflurane and alfentanil, time in the recovery unit, measurements of pain and nausea on the visual analog scale (VAS) up to 12 hours postoperatively and consumption of analgesics and antiemetics. Main outcome measures included intraoperative systolic blood pressure (BP); bradycardia; minimum alveolar concentration (MAC) of sevoflurane; maximum postoperative VAS scores of pain and nausea; time in recovery unit and total need of alfentanil, ketobemidone, dextropropoxyphene, and dixyrazine.

Ninety-seven patients were analyzed (48 in the ropivacaine group and 49 controls). The ropivacaine group experienced a significantly lower intraoperative systolic BP (104 +/- 6 vs. 112 +/- 7 mmHg), less need of sevoflurane (1.33 +/- 0.19 vs. 1.56 +/- 0.23) and shorter time in the recovery unit (67 +/- 9 vs. 76 +/- 16 minutes). Maximum VAS pain scores were 50 +/- 21 in the control group and 36 +/- 25 in the ropivacaine group, with a significantly lower consumption of opioids (ketobemidone) in the ropivacaine group (3.6 +/- 3.5 vs. 1.3 +/- 2.0 mg). No significant difference was observed regarding nausea or need of dixyrazine or dextropropoxyphene postoperatively.

SOURCE: Bergman L, Backmark I, Ones H, et al. Preoperative sub-Tenon"s capsule injection of ropivacaine in conjunction with general anesthesia in retinal detachment surgery. Ophthalmol 2007;114(11):2055-60.
Table of Contents






Progression to Severe ROP Predicted by Retinal Vessel Diameter

Researchers at the University of Pennsylvania and the Scheie Eye Institute assessed the predictive value of early retinal vascular diameter measurements for the development of severe retinopathy of prematurity (ROP) in high-risk preterm infants.

The investigators took digital fundus images of 78 eyes at risk for ROP using a noncontact camera during fundoscopic examination when infants were 31 to 34 weeks old. Vessel diameters were measured for the major superior and inferior temporal arteries and veins using VesselMap software. Mean vessel diameters from eyes that developed severe ROP requiring treatment were compared with those that either developed less severe ROP not requiring treatment or had no ROP.

All four major temporal retinal vessels showed significantly larger average diameters in the eyes that developed severe ROP requiring treatment. Multivariate analysis adjusted by birth weight, gestational age and chronologic age showed similar results. Early retinal vessel diameter measurements showed good predictive value for the progression to severe ROP requiring treatment (area under the receiver operating characteristic curve, 0.75 to 0.94).

SOURCE: Rabinowitz MP, Grunwald JE, Karp KA, et al. Progression to severe retinopathy predicted by retinal vessel diameter between 31 and 34 weeks of postconception age. Arch Ophthalmol 2007;125(11):1495-1500.
Table of Contents





BRIEFLY
  • JANUARY IS NATIONAL GLAUCOMA AWARENESS MONTH. January is Glaucoma Awareness Month, and the American Academy of Ophthalmology (AAO) and EyeCare America, a public service program of the Foundation of the AAO, in conjunction with the American Glaucoma Society and the Glaucoma Research Foundation, are reminding patients via their EyeSmart Campaign that knowing one"s risk for the disease can save sight. Higher-risk groups among Americans include those of African or Hispanic heritage and those with a family history of the illness. Older individuals with African ancestry are five times more likely to develop glaucoma and 14 to 17 times more likely to become blind than individuals of similar age with European ancestry. The risk for Hispanic Americans also rises markedly after age 60, and Americans of any ethnicity with a family history of the illness are four to nine times more susceptible. Yet a 2007 national survey for the EyeSmart campaign found that only 24 percent of people in ethnic groups at higher risk for glaucoma were aware of their risk and only 16 percent of those with a family history of eye disease, including glaucoma, could correctly identify the risk factors for those diseases. Those who have symptoms of or at risk for eye diseases including glaucoma should be advised to make regular visits to an ophthalmologist to determine how frequently their eyes should be examined. The AAO recommends that those with no symptoms or risk factors get a baseline screening at age 40 when the signs of disease and change in vision may begin. For more information, go to www.geteyesmart.org, the American Glaucoma Society web site at www.glaucomaweb.org and the Glaucoma Research Foundation web site at www.glaucoma.org.

  • PFIZER INITIATES PHASE II CLINICAL STUDY IN JAPAN FOR GLAUCOMA TREATMENT. Pfizer, Inc. has initiated a dose-ranging Phase II clinical study for PF-03187207, a new experimental medicine for the treatment of glaucoma, to be conducted in Japan. The drug is currently in an ongoing Phase II proof-of-concept study in the United States; the 28-day, double-masked, dose-ranging Japanese study will compare the safety and efficacy of PF-03187207 to Xalatan (latanoprost), a proprietary Pfizer product, in Japanese glaucoma patients. The compound was generated under the August 2004 collaboration agreement between Pfizer and NicOx, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogs for treating glaucoma. In the Japanese study, approximately 120 patients with primary open-angle glaucoma or ocular hypertension in one or both eyes will be randomized to treatment groups receiving different doses of PF-03187207 or Xalatan. The objective is to investigate the dose response, safety and efficacy of the compound in this patient population, with the primary endpoint of reducing IOP at Day 28 compared to baseline.
  • ACCUTOME PARTNERS WITH CANON MEDICAL EQUIPMENT. Accutome, Inc. has reached an agreement with Canon Medical Equipment to carry Canon"s full line of digital retinal cameras and diagnostic equipment in the United States. The highlight of the line is Canon"s CF-1, a powerful, high-resolution digital retinal camera that integrates a digital SLR camera from Canon's renowned EOS series with a high-sensitivity CMOS image-sensor that provides ultra-high-resolution images with superior detail, contrast and color fidelity. In addition to the CF-1, Accutome will also carry the CR-DGi, a non-mydriatic retinal camera. For more information call toll-free, 800-979-2020, or go to www.accutome.com.


Table of Contents

 

 

 


 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
The Check Yearly. See Clearly.(SM) marketing campaign is opening consumers' eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.